![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GSG2 |
Gene summary for GSG2 |
![]() |
Gene information | Species | Human | Gene symbol | GSG2 | Gene ID | 83903 |
Gene name | histone H3 associated protein kinase | |
Gene Alias | GSG2 | |
Cytomap | 17p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | A0PJ70 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83903 | GSG2 | HCC2 | Human | Liver | HCC | 3.10e-11 | 5.90e-01 | 0.5341 |
83903 | GSG2 | HCC5 | Human | Liver | HCC | 1.23e-09 | 5.99e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSG2 | SNV | Missense_Mutation | novel | c.1978N>C | p.Thr660Pro | p.T660P | Q8TF76 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
GSG2 | SNV | Missense_Mutation | novel | c.1978N>C | p.Thr660Pro | p.T660P | Q8TF76 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GSG2 | SNV | Missense_Mutation | novel | c.1978N>C | p.Thr660Pro | p.T660P | Q8TF76 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GSG2 | insertion | In_Frame_Ins | novel | c.1571_1572insGGACCAGAGGGT | p.Ser524_His525insAspGlnArgVal | p.S524_H525insDQRV | Q8TF76 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
GSG2 | deletion | Frame_Shift_Del | novel | c.1749delC | p.Gly585AlafsTer28 | p.G585Afs*28 | Q8TF76 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
GSG2 | SNV | Missense_Mutation | novel | c.1810N>C | p.Glu604Gln | p.E604Q | Q8TF76 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GSG2 | SNV | Missense_Mutation | rs748403043 | c.1931N>A | p.Arg644His | p.R644H | Q8TF76 | protein_coding | tolerated(1) | benign(0.001) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GSG2 | SNV | Missense_Mutation | c.151G>A | p.Asp51Asn | p.D51N | Q8TF76 | protein_coding | tolerated_low_confidence(0.5) | benign(0.001) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
GSG2 | SNV | Missense_Mutation | novel | c.2072N>T | p.Ser691Leu | p.S691L | Q8TF76 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MA-AA3W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSG2 | SNV | Missense_Mutation | c.2122N>C | p.Glu708Gln | p.E708Q | Q8TF76 | protein_coding | deleterious(0.03) | probably_damaging(0.933) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |